MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ajur.2025.05.001

Медицинская библиотека · Asian journal of urology · 2025

Development and validation of prostate-specific membrane antigen-adjusted Prostate Imaging Reporting and Data System: A new approach to enhancing the accuracy of diagnosing treatment-naïve primary prostate cancer.

Li Xiaoyuan, Song Jieping, Yao Xiaochen, Zhao Zhenyu, Zhang Qing, Li Rushuai, Zhang Pengjun, Wu Wenyu, Sun Hongwei, Ai Shuyue, Yang Fengjiao, Guo Hongqian, Shi Kuangyu, Afshar-Oromieh Ali, Zhang Longjiang, Lu Guangming, Civelek Ali Cahid, Wang Feng

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVE

The diagnostic efficacy of hybrid positron emission tomography (PET)/MRI in detecting primary prostate cancer (PCa) is limited due to the lack of a quantitative integrated analysis. A new Prostate Imaging Reporting and Data System (PI-RADS) incorporating prostate-specific membrane antigen (PSMA) PET for PET/MRI has been introduced to improve primary detection of PCa.

METHODS

One hundred and twenty consecutive patients with high clinical suspicion of PCa were enrolled in this prospective study to assess the diagnostic performance of PSMA-adjusted PI-RADS (PAPI-RADS) using 68Ga-PSMA-11 PET/MRI. Tumor PSMA uptake was assessed semi-quantitatively using the maximum and peak standardized uptake values. The PAPI-RADS was obtained by combining tumor PSMA uptake with PI-RADS. Patients were divided into two groups: a training group (90 patients) and a validation group (30 patients). The cutoff value of PSMA intensity was determined via receiver operating characteristic analysis. PAPI-RADS was then applied to the validation group. Histopathology was used as the gold standard to verify the diagnostic efficacy.

RESULTS

In the training group, PAPI-RADS detected more cases of PCa than PI-RADS. PAPI-RADS had a sensitivity of 99%, specificity of 100%, negative predictive value of 92%, and overall accuracy of 99%. PI-RADS had a sensitivity of 94%, specificity of 75%, negative predictive value of 64%, and overall accuracy of 90%. PAPI-RADS was significantly better than PI-RADS in detecting PCa (χ 2 =6.57, p=0.010). The external validation of this study confirmed the diagnostic efficacy of PAPI-RADS in PCa patients.

CONCLUSION

PAPI-RADS is significantly better than PI-RADS in detecting PCa. PAPI-RADS can improve the diagnostic accuracy of PCa detection, especially in patients with a PI-RADS score <3 lesions. PAPI-RADS can improve the accuracy of PCa diagnosis and avoid unnecessary biopsies.

Для цитирования: Li Xiaoyuan, Song Jieping, Yao Xiaochen, Zhao Zhenyu, Zhang Qing, Li Rushuai, Zhang Pengjun, Wu Wenyu, Sun Hongwei, Ai Shuyue, Yang Fengjiao, Guo Hongqian, Shi Kuangyu, Afshar-Oromieh Ali, Zhang Longjiang, Lu Guangming, Civelek Ali Cahid, Wang Feng. Development and validation of prostate-specific membrane antigen-adjusted Prostate Imaging Reporting and Data System: A new approach to enhancing the accuracy of diagnosing treatment-naïve primary prostate cancer.. Asian journal of urology. 2025. DOI: 10.1016/j.ajur.2025.05.001.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.